BC Cancer Agency Personalis, BC Cancer Partner on Study of ctDNA MRD Tests for Colorectal, Pancreatic Cancers The company will work with the Canadian health service to assess the potential health and economic impact of its molecular residual disease test. DLP Plus Single-Cell Sequencing Method Spreads From Canada to Cancer Labs Worldwide Premium The British Columbia-based developers are not trying to commercialize DLP Plus, but the platform is now being adopted in the US and UK. Structural Variants in Advanced Cancers Point to Effect of Treatment, Suggest Resistance Mechanisms The expressions of hundreds of genes in advanced cancers change in relation to nearby structural variant breakpoints, a new analysis has found. Roche, Canadian Organizations Launch Real-World Evidence Framework in British Columbia The aim within the initiative is to generate and assess real-world evidence, and use the data to support reimbursement for precision oncology therapies. Analysis of Advanced, Metastatic Tumors Indicates How Treatment Influences Mutational Profiles Exposure to DNA-damaging cancer treatments affects mutational signatures found in advanced and metastatic cancers, with alterations possibly indicating drug resistance. Mar 2, 2020 Genome BC Announces C$10M to Study Clinical Genomics Implementation May 1, 2018 CanSeq150 Sets Out to Sequence 150 Diverse Species Premium Feb 9, 2018 Canadian Group Finds Hybrid Capture Better Than Amplicon for Lymphoma Gene Panel Premium Dec 19, 2017 Breast Cancer Chemotherapy Response Linked to Homologous Recombination Deficiency Score May 11, 2017 Endometriosis Sequences Suggest Subset Contains Mutations to Cancer-Related Genes Apr 24, 2017 Ovarian Cancer Genomic Analysis Reveals Seven Disease-Stratifying Clusters Apr 10, 2017 Medulloblastoma Marked by Intra-Tumor Mutation Diversity Sep 23, 2016 Strand-Seq Analytical Pipeline Developed for Direct Haplotyping Premium May 27, 2016 Ovarian Cancer Cell Migration, Diversity Assessed in Phylogenetic Study Premium Feb 5, 2016 Separate Research Teams Find Evidence of Clonality in SEO Cancer Tumors Jan 13, 2016 British Columbia Pledges $2.1M in Funding for Personalized Cancer Therapy Program Oct 15, 2015 Data Published on First 100 Subjects in BC Cancer WGS Trial as Project Sets Sights on 5K Patients Premium May 5, 2015 IBM Collaborates with 14 Cancer Institutes to Decipher Genomic Data Mar 13, 2015 With New Funds, BC Cancer Agency Aims to Sequence 300 Patients for Personalized Onco-Genomics Trial Premium Apr 22, 2014 British Columbia Cancer Agency Agrees to Fund Genomic Health's Oncotype DX Apr 10, 2014 Genomics in the Journals: Apr 10, 2014 Feb 20, 2014 Genomics in the Journals: Feb 20, 2014 Jan 17, 2014 LED Medical, BC Cancer Agency, Genome British Columbia to Develop Test for Oral Cancer Jun 26, 2013 British Columbia Cancer Agency Funded $9.5M for Personalized Cancer Project Jun 7, 2013 UVic-Genome BC Proteomics Centre to Receive $4.2M in Canadian Government Funding Premium Load More Breaking News New Products Posted to GenomeWeb: Qiagen, Thermo Fisher, Bionano Genomics, BillionToOne, More People in the News at Illumina Ventures, Element Biosciences, Epigenomics, Exagen, More Genomic Approaches Boost Rare Disease Diagnoses in Middle Eastern Patient Population GeneDx to Raise $150M in Public and Direct Stock Offerings In Brief This Week: T2 Biosystems, Novacyt, OpGen, Dante Genomics, Nautilus Biotechnology, More The Scan Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups. Genome-Wide Analysis Sheds Light on Genetics of ADHD A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder. MicroRNA Cotargeting Linked to Lupus A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus. Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.